Rigorous R&D Creates Innovation within the Next-Generation Medical Implants Industry
Tissue-engineered biological solutions will gain traction as research and clinical studies establish their safety, efficacy and proper usage, finds Frost & Sullivan
MOUNTAIN VIEW, Calif., Oct. 19, 2015 /PRNewswire/ -- Advancements in materials for medical implants are improving as increasing patient needs, end-user demands and stringent regulatory approvals push for continuous research and development. The implant industry is striving to maximize the efficacy of existing orthopedic, cardiovascular, ophthalmic and orthodontic implants by synthesizing higher quality materials, optimizing design characteristics as well as enhancing biocompatibility, healing and clinical outcomes.
Analysis from Frost & Sullivan, Key Material Technologies for Next Generation Implants (https://www.frost.com/d65d), finds innovations in materials geared towards performance and lightweight characteristics. The use of novel hybrid materials and polymers, such as stimuli responsive polymers and self-healing materials will further propel invention.
For complimentary access to more information on this research, please visit: http://bit.ly/1LPxpqN.
"The need for materials with tunable properties, biocompatibility, inertness, and resistance to sterilization is accelerating innovations in materials for implants," said Technical Insights Senior Industry Analyst Aarthi Janakiraman. "Biologics and combination materials are gaining popularity for use in allografts, autografts and demineralized bone matrix in healthcare applications."
However, the commercialization of these solutions has been slow due to stringent regulations. In Europe and North America, this forces technology developers to meet both consumer expectations and material specifications. In addition, high costs and the challenges associated with scaling up the production of new materials are curbing adoption.
Implant manufacturers need to conduct clinical trials to establish the efficiency and functionality of materials obtain regulatory approval and facilitate commercialization. Furthermore, stakeholders must carry out research and clinical studies to validate the safety, effectiveness and suitable usage of biological materials – a potential game changer in the implants space.
"Collaborations will be a crucial step to steer advances in material technologies," concluded Janakiraman. "Material developers and medical device manufacturers from across the globe must join hands to design and bring-to-market effective materials to boost the long-term utility of implants."
Key Material Technologies for Next Generation Implants, a part of the TechVision (http://ww2.frost.com/research/technology/health-wellness) subscription, identifies and profiles 10 technologies expected to shape the medical device and imaging industry. The list includes technologies that are already in the market as well as recently commercialized technologies. This research throws light on technology capability, maturity, global research intensity, adoption over the short and medium terms, and funding activities.
Frost & Sullivan's global TechVision practice is focused on innovation, disruption and convergence that provides a variety of technology based alerts, newsletters and research services as well as growth consulting services. Its premier offering, the TechVision program, identifies and evaluates the most valuable emerging and disruptive technologies enabling products with near-term potential. A unique feature of the TechVision program is an annual selection of 50 technologies that can generate convergence scenarios, possibly disrupt the innovation landscape, and drive transformational growth. View a summary of our TechVision program by clicking on the following link: http://ifrost.frost.com/TechVision_Demo.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
- The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
- The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Contact Us: Start the discussion
Subscribe: Newsletter on "the next big thing"
Register: Gain access to visionary innovation
Key Material Technologies for Next Generation Implants
D65D
Contact:
Kayla Belcher
Corporate Communications – North America
P: 210.247.2450
F: 210.348.1003
Logo - http://photos.prnewswire.com/prnh/20151014/276848LOGO
SOURCE Frost & Sullivan
Share this article